Redeye updated their analysis of Idogen as company approaches clinical phase Idogen AB (publ) is a company that is developing tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response in the patient. As the company now approaches clinical phase with its most advanced development program IDO 8, Redeye is intensifying their coverage of Idogen and have published an updated analysis of Idogen AB. In summary, Redeye's report describes Idogen as a company developing novel treatments where there are large unmedical needs.

In the most advanced program, IDO 8, the company has developed a cell therapy for patients with Hemophilia A, who have developed antibodies, a k a "inhibitors". Against their vital factor VIII treatment. The first clinical study within this program has, as previously communicated, obtained regulatory approval in both Sweden and Norway.

The first patient is planned to be included in this phase 1/2a study during autumn. Another example that is highlighted in the analysis of the company's platform is the IDO T-program, where the researchers in the company is working to develop a new cell therapy for patients that are to have a kidney transplant. There is a risk that the patient develops an organ rejection and is currently treated, to minimize the risk, with immunosuppressants for long periods, which may lead to serious side effects.

Example of side effects can be e.g. severe infections or cancer. A pre-treatment with Idogen's cell therapy, could counteract the undesired immune reponse that leads to a rejection. There are several more potential uses for cell therapies from the company as the technology platform is adaptable; as the tolerogenic cells may be adapted to several different types of antigens causing problems for the patient.

The usage can thus be expanded to other diseases where the immune system attacks tissues or transplants in an unwanted way.